Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

CAR hits pothole

Sloan Kettering's pause with CAR T cell therapy hasn't affected Juno partners

April 21, 2014 7:00 AM UTC

Patient deaths prompted Memorial Sloan Kettering Cancer Center to briefly halt enrollment and update inclusion criteria for its CD19 directed chimeric antigen receptor T cell therapy. But partner Juno Therapeutics Inc. and other CAR players don't think this will affect development of similar therapies.

Adoptive cell therapies are widely seen as the next great advance in the treatment of cancer...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article